^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
199P - Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET )and V-ATPase.
Published date:
03/23/2023
Excerpt:
Pretreatment with omeprazole + tepotinib shows broad-spectrum tumor shrinkage in KRAS G12C sensitive and resistant to sotorasib (H358, H23) and in KRAS non-G12C cell lines (A549, H460).
